Brendon Neuen's Publications

About Brendon Neuen's Publications

Senior Research Fellow, Renal and Metabolic
  • Nephrologist and Director, Kidney Trials, Royal North Shore Hospital
  • Clinical Associate Professor, University of Sydney
  • Conjoint Associate Professor, UNSW Sydney
  • Ph.D. ,
  • MBBS(Hons),
  • MSc(Oxon),
  • FRACP,
  • FASN

  • Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS

    European Heart Journal Date published:

  • Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial

    European Heart Journal Date published:

  • Natriuretic peptides, kidney function and clinical outcomes in heart failure with mildly reduced or preserved ejection fraction: pooled data from the I-PRESERVE, TOPCAT, PARAGON and DELIVER trials

    European Heart Journal Date published:

  • Optimizing Clinical Outcomes Beyond Heart Failure With Intravenous Iron

    Journal of the American College of Cardiology Date published:

  • Canagliflozin and iron metabolism in the CREDENCE trial

    Nephrology Dialysis Transplantation Date published:

  • Use of, time to, and type of first add-on anti-hyperglycaemic therapy to metformin in Australia, 2018-2022

    British Journal of Clinical Pharmacology Date published:

  • Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials

    The Lancet Diabetes & Endocrinology Date published:

  • The Effects of Anti-Inflammatory Agents on Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Randomised Controlled Clinical Trials

    Heart, Lung and Circulation Date published:

  • Kidney and Cardiovascular Outcomes With SGLT2 Inhibitors and/or GLP-1 Receptor Agonists in Type 2 Diabetes

    Journal of the American College of Cardiology Date published:

  • Timing of Cardio-Kidney Protection With SGLT2 Inhibitors: Insights From 4 Large-Scale Placebo-Controlled Outcome Trials

    Circulation Date published:

  • An overview of the CANVAS Program and CREDENCE trial: The primary outcomes and key clinical implications for those managing patients with type 2 diabetes

    Diabetes, Obesity and Metabolism Date published:

  • Reframing Chronicity with Urgency in Chronic Kidney Disease Management

    Clinical Journal of the American Society of Nephrology Date published:

  • Effects of canagliflozin on total heart failure events across the kidney function spectrum: Participant-level pooled analysis from the CANVAS Program and CREDENCE trial

    European Journal of Heart Failure Date published:

  • Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

    Nephrology Dialysis Transplantation Date published:

  • Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

    Circulation Date published:

  • Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure

    Journal of the American College of Cardiology Date published: